10 results
Biologic Events Leading to Chronic GVHD #Pathophys #Honc #Pharm #GVHD #GraftVersusHostDisease #Therapeutic #Pathways #NEJM
GVHD #Pathophys #Honc ... #Pharm #GVHD #GraftVersusHostDisease ... Therapeutic #Pathways #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Survival #EBM #Honc ... #Osimertinib #NSCLC ... #Survival #NEJM
Signaling Mechanism of PD-1 and PD-L1 and Inhibition of PD-1 Signaling in Microsatellite-Instability–High Cancers. MHC1 denotes
Pathophysiology #Honc ... #Pharm #PD1 #PDL1 ... MicrosatelliteInstability #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Lung Cancer #EBM #Honc ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
Tumor Type #EBM #Honc ... #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
Immune Checkpoint–Blocking Antibodies Approved by the Food and Drug Administration #Pharm #Honc #Checkpoint #Blockade #FDA #Antibodies
Administration #Pharm ... #Honc #Checkpoint ... #Indications #NEJM
Diagnostic Algorithm for Non–Small-Cell Lung Cancer (NSCLC). The upper portion of the algorithm shows the morphologic
Non–Small-Cell Lung Cancer (NSCLC ... classification of NSCLC ... #Diagnosis #Honc ... #Algorithm #NSCLC ... #PDL1 #NEJM
Immunosuppressive Strategies for the Prevention or Treatment of Acute GVHD. Panel A shows several classic immunosuppressive
Pathophysiology #IM #Honc ... #Pharm #GVHD #GraftVersusHostDisease ... Immunosuppression #NEJM
Glucagonoma-Associated Rash - The rash involved the arms, genitals, and buttocks and had progressed to the
D) #Clinical #HONC ... Rash #Microscopy #CT ... #NEJM